Immunotherapy dendritic cell

Lasky, J. Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas in Pediatric Patients, 2005. 

Yu JS. Phase II Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients With Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System, 2001. 

The lactulosamine structure may also act in an immunoprotective fashion, by blocking the immunosuppressive galectin-1. Thus, a divalent lactulosamine (102) restored galectin-1-impaired activity and proliferation of activated cytotoxic T-lym-phocytes in vitro, and enhanced the efficiency of dendritic-cell immunotherapy in a rodent model of breast cancer." ... 

Lou E, Marshall J, Aklilu M, Cole D, et al. 2006. A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastasis of colorectal carcinoma. Clin Colorectal Cancer 5 ... 

For all kinds of immunotherapy the question of dose is still discussed controversially. Is a single dose more relevant or a cumulative dose The single and cumulative sublingual immunotherapy (SLIT) doses applied in published studies are from 5-fold up to several 100-fold higher than in subcutaneous immunotherapy [1], Considering the possible mechanisms of immunotherapies, especially on the dendritic cell level, a balance of both might be expected to be the most convenient. All kinds of application produce a concentration gradient... 

Feili-Hariri M, Falkner DH, Morel PA Polarization of naive T cells into Thl orTh2 by distinct cytokine-driven murine dendritic cell populations implications for immunotherapy. J Leukoc Biol 2005 78 656-64. 

Morisaki, T., K. Matsumoto, H. Onishi, H. Kuroki, E. Baba, A. Tasaki, M. Kubo, M. Nakamura, S. Inaba, K. Yamaguchi, M. Tanaka, and M. Katano (2003) Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients rationale, current progress, and perspectives. Hum Cell 16 175-182. 

Ludewing B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000 191 795-803. 

Thompson AG, Thomas R. Induction of immune tolerance by dendritic cells implications for preventative and therapeutic immunotherapy of autoimmune disease. Immunol Cell Biol 2002 80 509-519. 

Dendritic cells (DC) are important antigen-presenting cells (APC) that can prime naive T-cells and control lymphocyte-mediated adaptive immune responses with respect to magnitude, memory, and self-tolerance. Understanding the biology of these cells is central to the development of new generation immunotherapies for cancer and chronic infection. 

Adoptive dendritic cell-based immunotherapy represents a promising approach to overcoming peripheral tolerance against autologous tumor antigens and to maintaining protective antitumor immunity. The translation of successful preclinical studies, however, appears to be hampered by new complexities associated with the clinical situation. 

Cancer immunotherapy by genetically engineered dendritic cells that have been transfected witli genes encoding tumor-associated antigens provides an intriguing combination of gene tlierapy and immunotherapy . ... 

Gilboa E, Vieweg J (2004). Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199 251-263. 

Akiyama Y, Maruyama K, Nara N, Hojo T, Cheng JY, Mori T, Wiltrout RH, Yamaguchi K. Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters. Cancer Lett 2002 184 37—47. 

Nicolette CA et al. Dendritic cells for active immunotherapy optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine 2007 25 S2 B47 0. 

---